The Englander Institute for Precision Medicine (EIPM) is driving innovation in precision medicine through cutting-edge research, clinical applications, and outreach efforts. Our multi-tiered approach to precision medicine utilizes large-scale genomic sequencing and analysis, paired with functional biology to advance the diagnosis, characterization, and treatment of genetic diseases. This sequencing strategy enables us to identify specific targets for treatment. For the patients’ that require our services, the enrollment starts at the Institute through an Institutional Review Board-approved clinical trial. Afterward, we obtain samples of both their normal and tumor tissue and analyze these samples using genomic sequencing techniques. In our state of the art clinical genomics lab, all these data are analyzed to sign out the patients’ reports by specialized pathologists. In addition, we also include the integration of Organoids for multiple drug testing for better-targeted therapies. The results of our genomic analysis and patients’ medical history are reviewed by a multi-institutional Precision Medicine Tumor Board, which includes experts in medical oncology, pathology, computational biology, genetics, and ethics.The Tumor Board will collaboratively develop a treatment plan tailored to each patient, and EIPM will then share this plan with patients’ clinicians, who then discuss the results with the patient. Our physicians follow the patients to see how they are responding to therapy and this information is captured in a clinical database that helps the EIPM team discover and develop therapeutic approaches to benefit many more patients with cancer and other diseases.

In conjunction with esteemed Weill Cornell Medicine and our award-winning hospital, NewYork-Presbyterian, EIPM has been at the forefront of clinical cancer testing for years, continually improving and expanding our test platforms for clinical use. We are offering our tests to patients and we are also developing the technological methods to integrate genomic test data with patients’ Electronic Health Record (EHR). In 2016, EIPM produced, EXaCT-1, the first Whole Exome Sequencing test approved for cancer testing in New York State. Shortly thereafter, we produced a 50-gene panel test, called the Cancer Gene Mutation Panel (CGMP_50), which interrogates a targeted section of the genome, also approved by New York State. Currently, we are awaiting NYS approval for an additional two tests, Oncomine, which is a more comprehensive targeted gene panel using the NCI MATCH platform, and a Myeloid test. We anticipate that these tests will be available for clinical use very soon. We are also integrating EIPM protocols into standard care activities based on requests and support from our Department of Oncology and Meyer Cancer Center, to also include the integration of Organoids for drug testing. For further information on each of our clinical tests, please visit our pages on EXaCT-1CGMPOncomine, and Myeloid. Our goal is to make use of advanced gene-sequencing technologies to identify the genetic alterations that give rise to and drive each patient’s illness. Next-generation genomics, biobanking, and computational biology are all part of our process. The identification of specific genetic alteration, especially in cancer cells, will enable clinicians to most efficiently match new, biologically-targeted therapies to our patients. Our clinical genomics lab’s goal is to make use of advanced gene-sequencing technologies to identify the genetic alterations that give rise to and drive each patient’s illness. Next-generation genomics, biobanking, and computational biology are all part of our process.